Policy Watch: 20 Regulatory Updates — March 20, 2026
This update covers drug enforcement controlled substances regulatory policy changes relevant to cannabis clinicians. It highlights new scheduling of synthetic cannabinoids and benzodiazepine analogs. Clinicians should stay informed on these regulatory…
Policy Watch: 10 Regulatory Updates — March 18, 2026
This Policy Watch covers the DEA marijuana rescheduling 2026 proposal and other key regulatory updates affecting cannabis clinicians. The rescheduling could facilitate research and patient access by acknowledging medical utility. These regulatory changes…
Policy Watch: 16 Regulatory Updates — March 13, 2026
This update covers cannabis medicine regulations 2026, highlighting key controlled substances scheduling and Medicare policy changes. These regulatory updates impact clinical research and patient access. Cannabis clinicians should stay informed on…
Policy Watch: 16 Regulatory Updates — March 11, 2026
This update covers DEA scheduling synthetic cannabinoids and other controlled substances relevant to cannabis clinicians. Medicare and Medicaid policy changes also affect cannabis treatment reimbursement. These regulatory updates shape the clinical…
AM Policy Update: March 11, 2026 – DEA Rescheduling Marijuana
The DEA rescheduling marijuana update on March 11, 2026, marks a significant federal regulatory change. This update affects cannabis medicine by recognizing its medical potential. It highlights the evolving landscape of controlled substances and federal…
